# Hyperfine, Inc.

**HYPR**

Nasdaq; healthcare; SIC 3845, Electromedical & Electrotherapeutic Apparatus; CIK 0001833769

# D/E

**on the D/E boundary of 370 graded peers in healthcare**

rank 303 of 370; percentile 81.8; sampling error 2.5 points; lower is stronger

A B C D E

**D/E, the sloth**



| Scoreboard | |
|---|---|
| **Profitability** | D<br>percentile 68.5 |
| **Solvency** | C<br>percentile 56.6 |
| **Growth and financing** | C/D<br>percentile 57.5 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $55.3M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 18, 2026<br>216 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $0.77<br>2026-10-19; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 18, 2026*

We are an innovative health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence ("AI")-powered portable ultra-low-field ("ULF") magnetic resonance ("MR") brain imaging. Our Swoop® Portable MR Imaging® System ("Swoop® system") produces high-quality images at a significantly lower magnetic field strength than conventional magnetic resonance imaging ("MRI") scanners.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 68.5** | | | | | | |
| Gross profitability | 12.2% | 32.3% | | 73.0 | 371 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (13.4%) | (6.6%) | | 32.9 | 812 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Gross margin stability, five years | 48.2 pts | 2.8 pts | | 99.6 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 56.6** | | | | | | |
| Twelve-month failure probability | not computable | 0.06% | | | | |
| *liabilities and a nearby cover-page share count are required at 2026-06-30* | | | | | | |
| Altman Z double-prime | (16.31) | (0.30) | | 70.9 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 4.34x | 2.96x | | 42.3 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 57.5** | | | | | | |
| Revenue growth, three-year compound | 25.8% | 10.1% | | 25.9 | 414 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | (25.6%) | 2.1% | | 89.1 | 705 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *two annual share counts are required; found 0* | | | | | | |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 298 | C4 Therapeutics, Inc. (CCCC) | 80.5 | D/E | dilution, fortress balance sheet |
| 299 | Merck & Co., Inc. (MRK) | 80.8 | D/E | |
| 300 | Personalis, Inc. (PSNL) | 81.0 | D/E | |
| 301 | Lexicon Pharmaceuticals, Inc. (LXRX) | 81.3 | D/E | fortress balance sheet |
| 302 | Surgery Partners, Inc. (SGRY) | 81.6 | D/E | late filer |
| 303 | Hyperfine, Inc. (HYPR) | 81.8 | D/E | |
| 304 | Accuray Inc. (ARAY) | 82.1 | D/E | late filer |
| 305 | Moderna, Inc. (MRNA) | 82.4 | D/E | |
| 306 | SkinHealth Systems Inc. (SKIN) | 82.7 | E | |
| 307 | Stereotaxis, Inc. (STXS) | 82.9 | E | |
| 308 | Karyopharm Therapeutics Inc. (KPTI) | 83.2 | E | dilution, distress, fortress balance sheet |

## What the price implies

*at the 2026-10-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (43.2%) | 8.0% | 16 |
| Distance from 52-week high | (58.4%) | (31.9%) | 21 |
| EBIT to enterprise value | not computable | (1.6%) | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | not computable | 0.28 | |
| Sales to price | not computable | 0.31 | |
| Composite equity issuance, five years | not computable | 20.3% | |
| Relative strength against the sector, log excess return | (0.78) | (0.13) | 16 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $43.5M |
| Operating cash flow, four quarters | -$27.1M |
| Months of runway | 19.3 |
| Days since last periodic filing | 75 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $463,505 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $6.8M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 2 | assets | us-gaap:Assets | $55.3M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 3 | net income | us-gaap:NetIncomeLoss | -$35.6M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$27.9M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 5 | assets | us-gaap:Assets | $58.9M | 2024-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $13.6M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 7 | gross profit | us-gaap:GrossProfit | $5.9M | 2024-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $12.9M | 2024-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 9 | gross profit | us-gaap:GrossProfit | $4.8M | 2023-12-31 | 2025-03-17 | 10-K | 25-040281 |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $11.0M | 2023-12-31 | 2025-03-17 | 10-K | 25-040281 |
| 11 | gross profit | us-gaap:GrossProfit | $907,000 | 2022-12-31 | 2024-03-22 | 10-K | 24-035343 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $6.8M | 2022-12-31 | 2024-03-22 | 10-K | 24-035343 |
| 13 | gross profit | us-gaap:GrossProfit | -$1.2M | 2021-12-31 | 2023-03-22 | 10-K | 23-009159 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.5M | 2021-12-31 | 2023-03-22 | 10-K | 23-009159 |
| 15 | current assets | us-gaap:AssetsCurrent | $50.9M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $11.7M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$330.0M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$37.1M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 19 | book equity | us-gaap:StockholdersEquity | $41.0M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 20 | liabilities | us-gaap:Liabilities | $14.3M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.2M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$38.8M | 2024-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $383,000 | 2024-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$41.8M | 2023-12-31 | 2025-03-17 | 10-K | 25-040281 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $804,000 | 2023-12-31 | 2025-03-17 | 10-K | 25-040281 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$72.3M | 2022-12-31 | 2024-03-22 | 10-K | 24-035343 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $585,000 | 2022-12-31 | 2024-03-22 | 10-K | 24-035343 |
| 28 | depreciation amortization | us-gaap:Depreciation | $1.1M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 29 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$35.6M | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 30 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 31 | current assets | us-gaap:AssetsCurrent | $53.7M | 2024-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 32 | current liabilities | us-gaap:LiabilitiesCurrent | $8.7M | 2024-12-31 | 2026-03-18 | 10-K | 26-114044 |
| 33 | assets | us-gaap:Assets | $94.2M | 2023-12-31 | 2025-03-17 | 10-K | 25-040281 |
| 34 | assets | us-gaap:Assets | $134.1M | 2022-12-31 | 2024-03-22 | 10-K | 24-035343 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.